Huons Lab Merger Sparks Growing Unrest Among Minority Shareholders

Minority shareholders of Huons Global, the holding company, are strongly protesting Huons' recent decision to absorb and merge with its affiliate, Huons Lab. While Huons Global explained the merger as a strategic response to drug price reduction policies and pledged to communicate through shareholder meetings, minority shareholders continue to voice their strong opposition.

Details of the Merger and Shareholder Opposition

According to electronic disclosure systems on the 27th, Huons plans to distribute 3,825,327 new shares of Huons to Huons Lab shareholders instead of cash as part of the absorption merger. However, minority shareholders are vehemently opposing this, even submitting petitions. They argue that it is disadvantageous for Huons to absorb Huons Lab, given that Huons Lab is valued as a biotech asset with high future growth potential.

Background of the Merger and Stock Performance

The merger was approved by the board of directors on the 18th, with a merger ratio of 1:0.4256893. Following the merger announcement, the stock prices of Huons Global and Huons have shown divergent trends, indicating varied market interpretations of the transaction. Some speculate that the merger could be linked to the owner family's succession plan, as a lower corporate value for Huons Global would reduce the financial burden for the owner family to acquire additional shares. However, the company denies these speculations.

Huons' Stance and Minority Shareholders' Reactions

Huons Global emphasizes that the merger is a strategic decision to respond to the government's drug pricing reforms and enhance research and development capabilities. They assert that Huons possesses stable cash generation abilities and the capacity to manage the entire business process, including production, development, and regulatory approvals. Nevertheless, minority shareholders are protesting, viewing the merger structure as a transfer of growth assets from the holding company to the business entity.

Minority shareholders are preparing to submit petitions to the Financial Supervisory Service and the Korea Exchange. Huons Global plans to hold a meeting to gather shareholder opinions, though the date for this meeting has not yet been set.

Current Stock Status and Future Outlook

As of the current trading on the Korea Exchange, Huons Global's stock is trading at 33,800 won, down 4.79% from the previous day, while Huons closed at 32,450 won, up 0.93%. This stock performance reflects the market's ongoing reactions and investor concerns regarding the merger.

There is significant interest in how the minority shareholders' stance will evolve during the Huons and Huons Lab merger process and what impact the company's proposed measures will have. Moving forward, it will be crucial for shareholders to make informed decisions while closely monitoring the unfolding situation.